clinics combining glp-1 treatment and personal training Moving Forward Without GLP-1: A Behavioral Approach to Lasting Health GLP1-Injections | Hydrations Wellness

NCI-EGSSO-SSO-ESSO 2021

Side-by-Side Comparison Parameter Receptors Cagrilintide AMY1R/2R/3R + CTR Semaglutide GLP-1R Tirzepatide GLP-1R + GIPR Retatrutide GLP-1R + GIPR + Glucagon-R Parameter Half-life Cagrilintide ~7-8 days Semaglutide ~7 days Tirzepatide ~5 days Retatrutide ~6 days Parameter Dosing frequency Cagrilintide Once weekly Semaglutide Once weekly Tirzepatide Once weekly Retatrutide Once weekly Parameter Max studied dose Cagrilintide 4.5 mg/week (mono) Semaglutide 2.4 mg/week Tirzepatide 15 mg/week Retatrutide 12 mg/week Parameter Peak monotherapy weight loss Cagrilintide 11.8% at 68 wk Semaglutide 14.9-17% at 68 wk Tirzepatide 22.5% at 72 wk Retatrutide ~24% at 48 wk Parameter FDA status (June 2026) Cagrilintide Investigational Semaglutide Approved (2021) Tirzepatide Approved (2023) Retatrutide Investigational Parameter HbA1c reduction (T2D) Cagrilintide ~0.9 pp mono

However, individual results can vary, and more research is needed to fully understand its effects on skin aging

Research suggests specific strains have documented roles in metabolic health and GLP-1 production mechanisms: Akkermansia muciniphila has emerged as one of the most extensively researched bacterial strains for metabolic health, earning designation as a "next-generation probiotic" in scientific literature

15 Of important interest was their effects in weight loss even in non-diabetic patients

General information about the safe and effective use of NASCOBAL